AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

AbbVie Inc.NYSE: ABBV

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q2 FY2026 accounts payables of $1.2B rose 133.4% year over year, ahead of the -44.5% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -16.0% a year.

Context

  • Accounts payables amounted to 1.6% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +133.4% holds above the trailing-twelve-month pace of -44.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.2B+175.4% QoQ
Last fiscal yearDec 2025
$951M+437.3% YoY
LTMJun 2026
$740M-44.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+133.4%——
1 year+437.3%——
3-year CAGR-16.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
951M USD
Year-over-year change
+437.3%
4-year CAGR
-12.6%

Accounts Payables vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.5% is the 3rd highest of 5, against a peer median of +206.2%.
  • Accounts payables amounts to 1.1% of revenue for ABBV, versus a peer median of 0.0%.
ABBV Competitors
Accounts Payables for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$2.72B USD+14189.5%+29.4%2.7%
ABBVAbbVie Inc.LTM Jun 2026$740M USD-44.5%-16.0%1.1%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$450M USD+533.8%—0.9%
NVSNovartis AGLTM Jun 2026$194.29M USD-248.3%+14.9%0.3%
AMGNAmgen Inc.LTM Jun 2026$157M USD-121.4%+40.6%0.4%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD—+97.0%0.0%
MRKMerck & Co., Inc.LTM Jun 2026$0 USD——0.0%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding ABBV) —+206.2%+35.0%0.0%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.55B11.85B4.82B4.29B4.23B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
Deferred Income Tax(898M)(1.93B)(2.89B)(1.45B)(492M)
Stock-Based Compensation692M671M747M911M955M
Change in Working Capital(1.32B)(258M)2.81B(2.78B)(2.36B)
Accounts Receivables(1.32B)(1.46B)66M207M(1.49B)
Inventory(142M)(686M)(417M)(319M)(234M)
Accounts Payables1.63B1.61B3.84B177M951M
Other Working Capital(1.49B)278M(676M)(2.85B)(1.59B)
Other Non-Cash Items4.24B6.15B8.65B9.45B8.6B
Operating Cash Flow22.78B24.94B22.84B18.81B19.03B
Capital Expenditures(787M)(695M)(777M)(974M)(1.21B)
Acquisitions (Net)(1.9B)(794M)(1.22B)(17.49B)(204M)
Purchases of Investments(119M)(1.44B)(77M)(73M)(35M)
Sales of Investments98M1.53B55M555M76M
Other Investing Activities366M774M13M(2.84B)(5.27B)
Investing Cash Flow(2.34B)(623M)(2.01B)(20.82B)(6.64B)
Debt Repayment(8.41B)(12.43B)(4.15B)7.35B(327M)
Common Stock Issued0000172M
Common Stock Repurchased(934M)(1.49B)(1.97B)(1.71B)(980M)
Dividends Paid(9.26B)(10.04B)(10.54B)(11.03B)(11.66B)
Other Financing Activities(430M)(840M)(562M)172M68M
Financing Cash Flow(19.04B)(24.8B)(17.22B)(5.21B)(12.72B)
Effect of Forex Changes(97M)(62M)5M(65M)42M
Net Change in Cash1.3B(545M)3.61B(7.29B)(295M)
Free Cash Flow21.99B24.25B22.06B17.83B17.82B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.